Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant
Models, Molecular
0301 basic medicine
570
COVID-19/diagnosis
Protein Conformation
610
Antibodies, Monoclonal/chemistry
Cross Reactions
Antibodies, Viral
Epitopes/chemistry
SARS-CoV-2/immunology
Article
Epitopes
Structure-Activity Relationship
03 medical and health sciences
Neutralization Tests
antibody
Virology
Antibodies, Viral/chemistry
Humans
B.1.1.7
Spike Glycoprotein, Coronavirus/chemistry
Protein Binding/immunology
SARS-CoV-2
immune escape
Antibodies, Monoclonal
COVID-19
neutralization
Antibodies, Neutralizing/immunology
Antibodies, Neutralizing
neutralizing epitope
Virus
3. Good health
Angiotensin-Converting Enzyme 2/chemistry
Mutation
Spike Glycoprotein, Coronavirus
Angiotensin-Converting Enzyme 2
Cross Reactions/immunology
variant of concern
Virología
Protein Binding
DOI:
10.1016/j.immuni.2021.03.023
Publication Date:
2021-04-02T02:02:57Z
AUTHORS (29)
ABSTRACT
Interaction of the SARS-CoV-2 Spike receptor binding domain (RBD) with the receptor ACE2 on host cells is essential for viral entry. RBD is the dominant target for neutralizing antibodies, and several neutralizing epitopes on RBD have been molecularly characterized. Analysis of circulating SARS-CoV-2 variants has revealed mutations arising in the RBD, N-terminal domain (NTD) and S2 subunits of Spike. To understand how these mutations affect Spike antigenicity, we isolated and characterized >100 monoclonal antibodies targeting epitopes on RBD, NTD, and S2 from SARS-CoV-2-infected individuals. Approximately 45% showed neutralizing activity, of which ∼20% were NTD specific. NTD-specific antibodies formed two distinct groups: the first was highly potent against infectious virus, whereas the second was less potent and displayed glycan-dependant neutralization activity. Mutations present in B.1.1.7 Spike frequently conferred neutralization resistance to NTD-specific antibodies. This work demonstrates that neutralizing antibodies targeting subdominant epitopes should be considered when investigating antigenic drift in emerging variants.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (86)
CITATIONS (131)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....